Total Body PET 2021 conference [rescheduled] Sep 22, 2021 - Sep 24, 2021 — Virtual Meeting (online)
PET is Wonderful Annual Meeting 2021 Oct 26, 2021 12:00 AM — Virtual Meeting (online)
NRS Mental Health Network Annual Scientific Meeting 2021 Nov 02, 2021 09:00 AM - 05:00 PM — Royal College of Physicians, Edinburgh (and online)

eLearning

SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.


Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

Ms Lynne Gilfillan

Position: PhD student
Institute: University of Glasgow
Department: Department of Chemistry


Description of Phd:

 

Schizophrenia is a devastating illness that can affect as much as 1% of the population in developed countries. Antipsychotic drugs that target the dopamine receptor have been developed, however, these do not treat all the symptoms and have significant side effects. There is now evidence for glutamatergic dysfunction in schizophrenia and thus, the development of metabotropic glutamate Glu2/3 (mGlu2/3) receptor agonists could overcome the limitations of existing treatments. To exploit mGlu2/3 for the treatment of schizophrenia, biomarkers to probe glutamatergic transmission are urgently needed. The aim of this project is to develop new imaging agents for the mGlu2/3 site that could be used to evaluate novel glutamatergic drugs in vivo  and measure treatment response. Moreover, we plan to design and synthesise a high affinity precursor with multi-labelling positions that could be used for either PET or SPECT imaging. The SPECT studies involved with this project will be carried out in collaboration with Dr Sally Pimlott from the Glasgow Neuroimaging Research Group. The project will begin with the multi-step synthesis of a small library of novel diazepine-2-ones, compounds with structural motifs known to have affinity with mGlu2/3. Following biological evaluation of these, the most potent analogue with multi-labelling positions will be selected for development as both a PET and SPECT tracer. Successful tracers will then be used to study and develop a better understanding of glutamatergic transmission in schizophrenia.